Syndromic multiplex diagnostic, a method of simultaneously screening for multiple infectious diseases or genetic conditions, finds significant application in infectious disease management, particularly during outbreaks. Swiftly identifying various pathogens causing similar symptoms, such as fever or respiratory distress, this approach enables healthcare professionals to promptly implement appropriate infection control measures and treatment strategies. Especially crucial in settings such as hospitals, emergency rooms, and public health laboratories, syndromic testing aids in containing outbreaks, minimizing transmission, and ensuring optimal patient care through rapid and accurate diagnosis.
Global Syndromic Multiplex Diagnostic Market valued at USD 2.52 billion in 2023, is projected to reach 5.05 billion by 2031 and will grow at a CAGR of 6.1% during the forecast period of 2023-2030.
To know more, visit https://www.databridgemarketresearch.com/jp/reports/global-syndromic-multiplex-diagnostic-market
Below are the Top Syndromic Multiplex Diagnostic Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
BioFire Diagnostics
|
Known for their FilmArray system, BioFire specializes in syndromic multiplex diagnostic solutions. Their FilmArray panels can rapidly detect multiple pathogens from a single sample, aiding in quick diagnosis and treatment decisions in infectious disease management.
|
|
U.S.
|
In May 2020, BioFire Diagnostics (A Subsidiary of biomérieux SA) announced that they have received FDA Emergency use authorization for the BIOFIRE RP2.1 panel, which includes 22 pathogens that cause respiratory infections, including SARS-CoV-2 for COVID-19 disease. After this announcement, the company has enhanced their credibility in the market.
|
|
2.
|
F. Hoffmann-La Roche Ltd.
|
Roche offers syndromic multiplex diagnostic solutions through their cobas Liat and cobas Liat PCR systems. These systems enable rapid and accurate detection of infectious diseases at the point of care, facilitating timely interventions and patient management.
|
|
Europe, South America, Middle East and Africa, Asia-Pacific, and North America
|
In May 2020, F. Hoffmann-LA Roche Ltd announced that they have received the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for their product Cobas SARS-CoV-2 test, this product is used for the detection of SARS-CoV-2, the virus which causes COVID-19 disease. Also the product has received CE mark approval in the Europe region. After receiving approval company has enhanced their product portfolio and has generated adequate revenue.
|
|
3.
|
Luminex Corporation
|
Luminex provides syndromic multiplex diagnostic solutions through their ARIES system, offering rapid and scalable testing for infectious diseases and genetic conditions. Their technology allows for simultaneous detection of multiple targets, enhancing efficiency and accuracy in diagnostic workflows.
|
|
Europe, South America, Middle East and Africa, Asia-Pacific, and North America
|
In March 2020, Luminex Corporation announced that they have received FDA Emergency Use Authorization (EUA) for its NxTAG CoV Extended Panel; it is a multiplex diagnostic test which is used for the detection of SARS-CoV-2, the virus which causing COVID-19. After this announcement, the company has enhanced their credibility in the market.
|
|
4.
|
Cepheid
|
Cepheid is a leader in molecular diagnostics, offering the GeneXpert system for syndromic testing. With their Xpert assays, Cepheid enables rapid detection of various pathogens, including viruses and bacteria, aiding in the diagnosis of respiratory infections, sexually transmitted diseases, and other conditions.
|
|
Europe, Asia-Pacific, Middle East and Africa, North Ameica and North America
|
In January 2022, Cepheid (a subsidiary of Danaher) received a Health Canada license for Xpert Xpress CoV-2/Flu/RSV plus, a rapid molecular test to detect viruses causing COVID-19, Flu A, FluB and respiratory syncytial virus infections. The new plus version of the test provides a third gene target for SRA-CoV-2 detection. This has helped the company to increase its presence.
|
|
5.
|
QIAGEN
|
QIAGEN offers syndromic multiplex diagnostic solutions through their QIAstat-Dx platform. This system provides rapid and comprehensive testing for infectious diseases, respiratory pathogens, gastrointestinal infections, and more, contributing to efficient patient management and infection control.
|
|
Europe, North America, South America, Middle East and Africa, and Asia-Pacific
|
In April 2020, QIAGEN announced that they have launched QIAstat-Dx test kit which is used for the detection of SARS-CoV-2 coronavirus in Germany. It is the first syndromic testing solution to obtain derogation in Germany. After launching new product company enhanced their product portfolio and generates adequate revenue.
|
Conclusion
In the rapidly evolving syndromic multiplex diagnostic market, companies such as BioFire Diagnostics, F. Hoffmann-La Roche Ltd., Luminex Corporation, Cepheid, and QIAGEN play pivotal roles. Through their innovative technologies and platforms, these companies enable healthcare professionals to swiftly and accurately diagnose multiple infectious diseases and genetic conditions from a single sample. Their contributions not only enhance patient care by facilitating timely interventions but also aid in outbreak management and infection control measures. As these companies continue to advance their capabilities, the Syndromic Multiplex Diagnostic Market stands poised for further growth, promising greater efficiency and effectiveness in disease detection and management.
